AROG Pharmaceuticals

Executive Summary

AROG Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing crenolanib, a potent FLT3 inhibitor, for patients with high-risk acute myeloid leukemia (AML). Founded in 2017 and headquartered in Dallas, Texas, the company has treated over 400 patients with crenolanib across clinical studies, demonstrating its commitment to addressing an unmet need in AML. The company is advancing towards a pivotal Phase III trial evaluating crenolanib as maintenance therapy following allogeneic hematopoietic stem cell transplantation (HSCT) in FLT3-mutated AML patients. This trial design leverages encouraging clinical data from earlier studies and aims to improve outcomes in a high-risk population with limited treatment options. AROG's focused pipeline and the targeted mechanism of crenolanib position the company as a potential leader in post-transplant AML maintenance therapy, though it remains a private entity without disclosed financing or valuation.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Pivotal Phase III Trial for Post-HSCT Maintenance70% success
• H2 2026Presentation of Updated Clinical Data from Ongoing Studies80% success
• Q4 2026Strategic Partnership or Licensing Agreement40% success